Mandatory Training Debated for Opioid Safety

BY ELIZABETH MECHCATIE

College Park, Md. — Special training in safe prescription of long-acting opioid drugs, as well as the use of patient-prescriber agreements, could be required to earn federal approval to prescribe such products, under proposals discussed by an industry working group.

The working group presented those and other options at a public meeting held by the Food and Drug Administration. The meeting was part of an initiative to develop a class-wide risk evaluation and mitigation strategy (REMS) for long-acting opioid drugs.

The FDA last February informed manufacturers of long-acting opioid products that they would have to develop a single



Some physicians would opt out of training, thus reducing access to the drugs for patients who need them.

DR. JENKINS

REMS for the drug class. The FDA wants to reduce the potential for abuse, misuse, overdose, and addiction associated with the use of the products and to ensure that their benefits outweigh their risks.

Under one element of the plan being-considered, clinicians seeking Drug Enforcement Agency registration to prescribe schedule II controlled substances would be required to certify that they were trained to safely prescribe and choose the appropriate patients for the drugs. Currently, there is no training requirement for a physician to obtain DEA registration. Giving the DEA such authority would require an act of Congress, according to one of the industry working group representatives.

While efforts to pass such legislation are underway, the working group members noted, voluntary programs could be developed, possibly with medical specialty societies.

Requiring such training raises the concern that some physicians would opt out of training—thus reducing access to the drugs for patients who need them, said Dr. John Jenkins, director of the Office of New Drugs, in the FDA's Center for Drug Evaluation and Research.

The REMS program's goals are to ensure that the drugs' risks don't exceed their benefits, while ensuring access for patients who need them, Dr. Jenkins noted during a press briefing after the meeting.

The drugs to be included in the REMS are brand name and generic products that contain fentanyl, hydromorphone, methadone, morphine, oxycodone, and oxymorphone. Among the problems associated with those products include their use in patients who are non–opioid tolerant or otherwise inappropriately selected, as well as the drugs' misuse and abuse.

Dr. Jenkins cited the example of pain treatment with methadone—which,

when taken too frequently, can result rapidly in an overdose.

Short-acting opioid products are not included in the discussion. But meeting participants expressed concern that an effective REMS for the long-acting products could shift misuse and abuse to the shorter-acting agents.

Other ideas proposed by the industry working group for the REMS include:


► A patient-prescriber agreement, which

would serve as a tool to facilitate a discussion between physicians and patients.

- ▶ A medication information sheet.
- ▶ Metrics to assess the impact of the REMS. There should be a measure to determine whether the REMS impedes patients' access to appropriate medication, the working group noted.

The industry working group made no definitive conclusions at the meeting, however, and it has not developed a final plan for the REMS.

Dr. Jenkins said he couldn't predict when the REMS would be finalized. But an FDA advisory panel will meet in the spring to discuss the elements of the proposed REMS, to solicit advice from experts, and to hear public comment, he added. Until a final REMS is approved, Dr. Jenkins said, the FDA will require an interim REMS for any other products in the drug class.



"I take SYMBICORT before breakfast and I'm breathing better by my first cup of coffee."

— Bruce, living with COPD for 10 years

BRUCE, AGE 70

- Prescribed an anticholinergic and oxygen therapy as needed, but was still complaining of shortness of breath, particularly in the morning
- Doctor added SYMBICORT 160/4.5 mcg, 2 inhalations twice daily to his treatment regimen and now he's doing more with each day

Find out how sustained control* with rapid improvement in lung function at each dose^{12,1} can help your patients do more.

Step up their treatment with SYMBICORT.



A reassuring sense of control

* In a 12-month clinical study, SYMBICORT improved predose forced expiratory volume in 1 second (FEV-), 1-hour postdose FEV-, serial FEV-, (to measure onset of effect), AM peak expiratory flow, and reduced COPD symptoms and rescue albuterol use

' Mean percent change from baseline FEV-, was measured at day of randomization, and months 6 and 12.

Important Safety Information

- For patients with chronic obstructive pulmonary disease (COPD), the approved dosage of SYMBICORT is 160/4.5 mcg, 2 inhalations twice daily
- SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
- The most common adverse events ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection

Indication

 SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

Please see Brief Summary of full Prescribing Information, including boxed WARNING, on adjacent pages.

For more information, visit www.MySymbicort.com or call the AstraZeneca Information Center at 1-800-236-9933.

References: 1. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofludisease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549-565. 2. Data on File, 273071, AZPLP.

SYMBICORT is a registered trademark of the AstraZeneca group of companies. ©2009 AstraZeneca LP. All rights reserved. 291494 11/09

